Natural Alternatives International Reports 10% Sales Increase but Faces $20.7 Million Net Loss

Natural Alternatives International, Inc. (NAI) reported a consolidated net sales increase of 10% for the fiscal year ending June 30, 2026, reaching $142.5 million, compared to $129.9 million in the previous fiscal year. The growth was primarily driven by an 11% rise in private-label contract manufacturing sales, which accounted for 94% of total revenue. However, the company experienced a net loss of $20.7 million, a significant increase from the $13.6 million loss reported in fiscal 2025. This loss was largely attributed to a non-cash impairment charge of $10.4 million related to the company's manufacturing facility in Carlsbad, California, as well as increased selling, general, and administrative expenses.

In terms of operational changes, NAI has been focusing on diversifying its customer base and expanding its product offerings. The company launched two new products, CarnoSyn® 4X and TriBsyn®, which utilize proprietary technology to enhance beta-alanine bioavailability while minimizing side effects. These products are positioned to penetrate the Wellness and Healthy Aging markets, as well as the Sports Nutrition sector. Despite these initiatives, the company faced challenges, including a material downward revision in projected orders from one of its largest customers, which has raised concerns about its ability to comply with financial covenants in its new credit facility.

The company’s customer concentration remains high, with two customers accounting for 52% of total net sales in fiscal 2026. This dependency poses a risk, as the loss of either customer could significantly impact financial performance. NAI's employee count stood at 219 in the U.S. as of June 30, 2026, with an additional 82 employees in its European subsidiary. The company is actively seeking to improve operational efficiencies and reduce costs, including plans to sell its Carlsbad manufacturing facility to enhance liquidity and manage cash flows.

Looking ahead, NAI anticipates continued challenges in fiscal 2027, including potential net losses, as it navigates the impacts of inflation, supply chain pressures, and geopolitical uncertainties. The company is focused on leveraging its certified facilities to enhance service offerings and is exploring strategic alternatives to maximize shareholder value. Management has expressed optimism about the potential for growth through the commercialization of its beta-alanine patent estate and the introduction of new product lines, although the success of these initiatives remains uncertain.